Evidence map›Paper›PMID 39353903›Full record

ArticleNature communications2024

Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy.

Weiyue Zheng, Wanda Marini, Kiichi Murakami, Valentin Sotov, Marcus Butler, Chiara Gorrini, Pamela S Ohashi, Michael Reedijk

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Caspase-1 in cancer and inflammatory diseases: a potential therapeutic target.Apoptosis : an international journal on programmed cell death · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Weiyue Zheng *Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0009-0000-6485-9488
Wanda Marini *Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Kiichi MurakamiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Valentin SotovPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Marcus ButlerPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-9840-7057
Chiara GorriniPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-5239-6671
Pamela S OhashiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Michael ReedijkPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. Michael.Reedijk@uhn.ca.ORCID 0000-0002-4305-723X

Funding

Canadian Cancer Society Research Institute (Société Canadienne du Cancer) 707511
6 · The paper itself

Abstract

Tumor immune microenvironment (TIME) spatial organization predicts outcome and therapy response in triple-negative breast cancer (TNBC). An immunosuppressive TIME containing elevated tumor-associated macrophages (TAM) and scarce CD8+ T cells is associated with poor outcome, but the regulatory mechanisms are poorly understood. Here we show that ETS1-driven caspase-1 expression, required for IL1β processing and TAM recruitment, is negatively regulated by estrogen receptors alpha (ERα) and a defining feature of TNBC. Elevated tumoral caspase-1 is associated with a distinct TIME characterized by increased pro-tumoral TAMs and CD8+ T cell exclusion from tumor nests. Mouse models prove the functional importance of ERα, ETS1, caspase-1 and IL1β in TIME conformation. Caspase-1 inhibition induces an immunoreactive TIME and reverses resistance to immune checkpoint blockade, identifying a therapeutically targetable mechanism that governs TNBC spatial organization.

Indexed as

Caspase 1ImmunotherapyTriple Negative Breast NeoplasmsTumor-Associated MacrophagesAnimalsCD8-Positive T-LymphocytesCell Line, TumorEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsInterleukin-1betaMiceProto-Oncogene Protein c-ets-1Tumor MicroenvironmentCaspase 1ESR1 protein, humanEstrogen Receptor alphaETS1 protein, humanImmune Checkpoint InhibitorsInterleukin-1betaProto-Oncogene Protein c-ets-1

Identifiers

PMID39353903
PMCPMC11445480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.